Literature DB >> 18295562

Influence of short-term adenoviral vector and prolonged lentiviral vector mediated bone morphogenetic protein-2 expression on the quality of bone repair in a rat femoral defect model.

Mandeep Singh Virk1, Augustine Conduah, Sang-Hyun Park, Nancy Liu, Osamu Sugiyama, Anna Cuomo, Christine Kang, Jay R Lieberman.   

Abstract

The objective of this study was to compare the efficacy of adenoviral and lentiviral regional gene therapy in a rat critical sized femoral defect model. The healing rates and quality of bone repair of femoral defects treated with syngeneic rat bone marrow cells (RBMCs) transduced with either lentiviral vector (Group I) or adenoviral vector (Group II) expressing bone morphogenetic protein-2 (BMP-2) gene were assessed. RBMCs transduced with the adenoviral vectors produced more than 3 times greater (p<0.001) BMP-2 when compared to RBMCs transduced with lentiviral vectors in an in vitro evaluation. Serial bioluminescent imaging demonstrated short duration luciferase expression (less than 3 weeks) in defects treated with RBMCs co-transduced with two adenoviral vectors (Group IV; adenovirus expressing BMP-2 and luciferase [Ad-BMP-2+Ad-Luc]). In contrast, the luciferase signal was present for 8 weeks in defects treated with RBMCs co-transduced with two lentiviral vectors (Group III; lentivirus expressing BMP-2 and luciferase gene [LV-BMP-2+LV-Luc]). There were no significant differences with respect to the radiological healing rates (p=0.12) in defects treated with lentiviral versus adenoviral mediated BMP-2 gene transfer. Biomechanical testing of healed Group I femoral specimens demonstrated significantly higher energy to failure (p<0.05) when compared to Group II defects. Micro CT analysis revealed higher bone volume/tissue volume fraction (p=0.04) in Group I defects when compared to Group II defects. In conclusion, prolonged BMP-2 expression associated with lentiviral mediated gene transfer demonstrated a trend towards superior quality of bone repair when compared to adenoviral mediated transfer of BMP-2. These results suggest that the bone repair associated with regional gene therapy is influenced not just by the amount of protein expression but also by duration of protein production. This observation needs validation in a more biologically challenging environment where differences in healing rates and quality of bone repair are more likely to be significantly different.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295562     DOI: 10.1016/j.bone.2007.12.216

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  33 in total

1.  Enhanced adenovirus transduction of hMSCs using 3D hydrogel cell carriers.

Authors:  Alexander J Neumann; Josh Schroeder; Mauro Alini; Charles W Archer; Martin J Stoddart
Journal:  Mol Biotechnol       Date:  2013-02       Impact factor: 2.695

2.  Ex vivo regional gene therapy with human adipose-derived stem cells for bone repair.

Authors:  Venus Vakhshori; Sofia Bougioukli; Osamu Sugiyama; Hyunwoo P Kang; Amy H Tang; Sang-Hyun Park; Jay R Lieberman
Journal:  Bone       Date:  2020-07-02       Impact factor: 4.398

Review 3.  Gene therapy for the regeneration of bone.

Authors:  Christopher Evans
Journal:  Injury       Date:  2011-04-13       Impact factor: 2.586

4.  "Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.

Authors:  Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

5.  LvBMP-2 gene-modified BMSCs combined with calcium phosphate cement scaffolds for the repair of calvarial defects in rats.

Authors:  Chao Zhu; Qing Chang; Duohong Zou; Wenjie Zhang; Shaoyi Wang; Jun Zhao; Wenwen Yu; Xiuli Zhang; Zhiyuan Zhang; Xinquan Jiang
Journal:  J Mater Sci Mater Med       Date:  2011-06-18       Impact factor: 3.896

Review 6.  Gene therapy for bone healing.

Authors:  Christopher H Evans
Journal:  Expert Rev Mol Med       Date:  2010-06-23       Impact factor: 5.600

7.  Gene Therapy for Bone Repair Using Human Cells: Superior Osteogenic Potential of Bone Morphogenetic Protein 2-Transduced Mesenchymal Stem Cells Derived from Adipose Tissue Compared to Bone Marrow.

Authors:  Sofia Bougioukli; Osamu Sugiyama; William Pannell; Brandon Ortega; Matthew H Tan; Amy H Tang; Robert Yoho; Daniel A Oakes; Jay R Lieberman
Journal:  Hum Gene Ther       Date:  2018-03-14       Impact factor: 5.695

8.  Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair.

Authors:  F Alaee; O Sugiyama; M S Virk; H Tang; H Drissi; A C Lichtler; J R Lieberman
Journal:  Gene Ther       Date:  2013-11-28       Impact factor: 5.250

9.  Long-term tracking of segmental bone healing mediated by genetically engineered adipose-derived stem cells: focuses on bone remodeling and potential side effects.

Authors:  Chin-Yu Lin; Yu-Han Chang; Li-Yu Sung; Chiu-Ling Chen; Shih-Yeh Lin; Kuei-Chang Li; Tzu-Chen Yen; Kun-Ju Lin; Yu-Chen Hu
Journal:  Tissue Eng Part A       Date:  2014-05       Impact factor: 3.845

10.  Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model.

Authors:  Mandeep S Virk; Farhang Alaee; Hezhen Tang; Michael S Ominsky; Hua Zhu Ke; Jay R Lieberman
Journal:  J Bone Joint Surg Am       Date:  2013-04-17       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.